Discovery of Selective Small Molecule Inhibitors of Monoacylglycerol Acyltransferase 3

Journal of Medicinal Chemistry

Volumn 58, Issue 18, 2015, Pages 7164-7172

  Huard, Kim ^a   Londregan, Allyn T ^a   Tesz, Gregory ^a   Bahnck, Kevin B ^a   Magee, Thomas V ^a   Hepworth, David ^a   Polivkova, Jana ^a   Coffey, Steven B ^a   Pabst, Brandon A ^a   Gosset, James R ^a   Nigam, Anu ^a   Kou, Kou ^a   Sun, Hao ^a   Lee, Kyuha ^a   Herr, Michael ^a   Boehm, Markus ^a   Carpino, Philip A ^a   Goodwin, Bryan ^a   Perreault, Christian ^a   Li, Qifang ^a   Jorgensen, Csilla C ^a   Tkalcevic, George T ^a   Subashi, Timothy A ^a   Ahn, Kay ^a   more..

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLGLYCEROL PALMITOYLTRANSFERASE; ACYLTRANSFERASE INHIBITOR; DEUTERIUM; DIACYLGLYCEROL ACYLTRANSFERASE 1; DIACYLGLYCEROL ACYLTRANSFERASE 2; GLYCEROL; MONOACYLGLYCEROL ACYLTRANSFERASE 3; N (2 CYCLOBUTYL 2H 1,2,3 TRIAZOL 4 YL) 2 [2 (3 METHOXYPHENYL)ACETYL]ISOINDOLINE 5 SULFONAMIDE; UNCLASSIFIED DRUG; 2-ACYLGLYCEROL O-ACYLTRANSFERASE; ACYLTRANSFERASE; DIACYLGLYCEROL ACYLTRANSFERASE; ISOINDOLE DERIVATIVE; PF-06471553; SULFONAMIDE; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; ENZYME INHIBITION; IC50; IN VIVO STUDY; LIPID HOMEOSTASIS; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN EXPRESSION; PROTEIN FUNCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL CULTURE; CHEMISTRY; DOG; GENETICS; HUMAN; MOLECULAR DOCKING; STRUCTURE ACTIVITY RELATION; TRANSGENIC MOUSE;

ACYLTRANSFERASES; ANIMALS; CELLS, CULTURED; DIACYLGLYCEROL O-ACYLTRANSFERASE; DOGS; HUMANS; ISOINDOLES; MICE, TRANSGENIC; MOLECULAR DOCKING SIMULATION; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; TRIGLYCERIDES;

EID: 84942314032     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b01008     Document Type: Article

References (39)

1. Unger, R. H. Lipotoxic diseases Annu. Rev. Med. 2002, 53, 319-336 10.1146/annurev.med.53.082901.104057
2. Friedman, J. Fat in all the wrong places Nature 2002, 415, 268-269 10.1038/415268a
3. Schaffer, J. E. Lipotoxicity: when tissues overeat Curr. Opin. Lipidol. 2003, 14, 281-287 10.1097/00041433-200306000-00008
4. Shi, Y.; Cheng, D. Beyond triglyceride synthesis: the dynamic functional roles of MGAT and DGAT enzymes in energy metabolism Am. J. Physiol. Endocrinol. Metab. 2009, 297, E10-E18 10.1152/ajpendo.90949.2008
5. Yen, C. L.; Stone, S. J.; Koliwad, S.; Harris, C.; Farese, R. V., Jr Thematic review series: glycerolipids. DGAT enzymes and triacylglycerol biosynthesis J. Lipid Res. 2008, 49, 2283-2301 10.1194/jlr.R800018-JLR200
6. Cases, S.; Smith, S. J.; Zheng, Y. W.; Myers, H. M.; Lear, S. R.; Sande, E.; Novak, S.; Collins, C.; Welch, C. B.; Lusis, A. J.; Erickson, S. K.; Farese, R. V., Jr. Identification of a gene encoding an acyl CoA: diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 13018-13023 10.1073/pnas.95.22.13018
7. Cases, S.; Stone, S. J.; Zhou, P.; Yen, E.; Tow, B.; Lardizabal, K. D.; Voelker, T.; Farese, R. V., Jr. Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members J. Biol. Chem. 2001, 276, 38870-38876 10.1074/jbc.M106219200
8. Cao, J.; Lockwood, J.; Burn, P.; Shi, Y. Cloning and functional characterization of a mouse intestinal acyl-CoA: monoacylglycerol acyltransferase, MGAT2 J. Biol. Chem. 2003, 278, 13860-13866 10.1074/jbc.M300139200
9. Yen, C. L.; Farese, R. V., Jr. MGAT2, a monoacylglycerol acyltransferase expressed in the small intestine J. Biol. Chem. 2003, 278 (28) 18532-18537 10.1074/jbc.M301633200
10. Cao, J.; Burn, P.; Shi, Y. Properties of the mouse intestinal acyl-CoA:monoacylglycerol acyltransferase, MGAT2 J. Biol. Chem. 2003, 278 (28) 25657-25663 10.1074/jbc.M302835200
11. Yen, C. L.; Stone, S. J.; Cases, S.; Zhou, P.; Farese, R. V., Jr. Identification of a gene encoding MGAT1, a monoacylglycerol acyltransferase Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 8512-8517 10.1073/pnas.132274899
12. Cheng, D.; Nelson, T. C.; Chen, J.; Walker, S. G.; Wardwell-Swanson, J.; Meegalla, R.; Taub, R.; Billheimer, J. T.; Ramaker, M.; Feder, J. N. Identification of acyl coenzyme A: monoacylglycerol acyltransferase 3, an intestinal specific enzyme implicated in dietary fat absorption J. Biol. Chem. 2003, 278 (16) 13611-13614 10.1074/jbc.C300042200
13. DeVita, R. J.; Pinto, S. Current Status of the Research and Development of Diacylglycerol O-Acyltransferase 1 (Dgat1) Inhibitors J. Med. Chem. 2013, 56, 9820-9825 10.1021/jm4007033
14. Dow, R. L. Acyl-Coa: Diacylglycerol Acyltransferase-1 Inhibition as an Approach to the Treatment of Type 2 Diabetes RSC Drug Discovery Ser. 2012, 27, 215-248 10.1039/9781849735322-00215
15. Birch, A. M.; Buckett, L. K.; Turnbull, A. V. Curr. Opin. Drug Discovery Dev. 2010, 13, 489
16. Choi, C. S.; Savage, D. B.; Kulkarni, A.; Yu, X. X.; Liu, Z. X.; Morino, K.; Kim, S.; Distefano, A.; Samuel, V. T.; Neschen, S.; Zhang, D.; Wang, A.; Zhang, X. M.; Kahn, M.; Cline, G. W.; Pandey, S. K.; Geisler, J. G.; Bhanot, S.; Monia, B. P.; Shulman, G. I. Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance J. Biol. Chem. 2007, 282 (31) 22678-22688 10.1074/jbc.M704213200
17. Liu, Y.; Millar, J. S.; Cromley, D. A.; Graham, M.; Crooke, R.; Billheimer, J. T.; Rader, D. J. Knockdown of acyl-CoA:diacylglycerol acyltransferase 2 with antisense oligonucleotide reduces VLDL, TG and ApoB secretion in mice Biochim. Biophys. Acta, Mol. Cell Biol. Lipids 2008, 1781 (3) 97-104 10.1016/j.bbalip.2008.01.001
18. Yu, X. X.; Murray, S. F.; Pandey, S. K.; Booten, S. L.; Bao, D.; Song, X. Z.; Kelly, S.; Chen, S.; McKay, R.; Monia, B. P.; Bhanot, S. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice Hepatology 2005, 42 (2) 362-371 10.1002/hep.20783
19. DGAT2 inhibitors, which exhibit robust in vivo efficacy including reduction in plasma TAG and total cholesterol, have been recently reported: Futatsugi, K.; Kung, D. W.; Orr, S. T. M.; Cabral, S.; Hepworth, D.; Aspnes, G.; Bader, S.; Bian, J.; Boehm, M.; Carpino, P. A.; Coffey, S. B.; Dowling, M. S.; Herr, M.; Jiao, W.; Lavergne, S. Y.; Li, Q.; Clark, R. W.; Erion, D.; Kou, K.; Lee, K.; Pabst, B. A.; Perez, S. M.; Purkal, J.; Jorgensen, C. C.; Goosen, T. C.; Gosset, J. R.; Niosi, M.; Pettersen, J. C.; Pfefferkorn, J. A.; Ahn, K.; Goodwin, B. Discovery and Optimization of Imidazopyridine-based Inhibitors of Diacylglycerol Acyltransferase 2 (DGAT2). J. Med. Chem., accepted. DOI: 10.1021/acs.jmedchem.5b01006.
20. Yen, C. L.; Cheong, M. L.; Grueter, C.; Zhou, P.; Moriwaki, J.; Wong, J. S.; Hubbard, B.; Marmor, S.; Farese, R. V., Jr. Deficiency of the intestinal enzyme acyl CoA:monoacylglycerol acyltransferase-2 protects mice from metabolic disorders induced by high-fat feeding Nat. Med. 2009, 15 (4) 442-446 10.1038/nm.1937
21. Barlind, J. G.; Buckett, L. K.; Crosby, S. G.; Davidsson, Ö.; Emtenäs, H.; Ertan, A.; Jurva, U.; Lemurell, M.; Gutierrez, P. M.; Nilsson, K.; O'Mahony, G.; Petersson, A. U.; Redzic, A.; Wågberg, F.; Yuan, Z.-Q. Identification and design of a novel series of MGAT2 inhibitors Bioorg. Med. Chem. Lett. 2013, 23, 2721-2726 10.1016/j.bmcl.2013.02.084
22. Scott, J. S.; Berry, D. J.; Brown, H. S.; Buckett, L.; Clarke, D. S.; Goldberg, K.; Hudson, J. A.; Leach, A. G.; MacFaul, P. A.; Raubo, P.; Robb, G. Achieving improved permeability by hydrogen bond donor modulation in a series of MGAT2 inhibitors MedChemComm 2013, 4, 1305-1311 10.1039/c3md00156c
23. Sato, K.; Takahagi, H.; Yoshikawa, T.; Morimoto, S.; Takai, T.; Hidaka, K.; Kamaura, M.; Kubo, O.; Adachi, R.; Ishii, T.; Maki, T.; Mochida, T.; Takekawa, S.; Nakakariya, M.; Amano, N.; Kitazaki, T. Discovery of a Novel Series of N-Phenylindoline-5-sulfonamide Derivatives as Potent, Selective, and Orally Bioavailable Acyl CoA:Monoacylglycerol Acyltransferase-2 Inhibitors J. Med. Chem. 2015, 58, 3892-3909 10.1021/acs.jmedchem.5b00178
24. Cao, J.; Cheng, L.; Shi, Y. Catalytic properties of MGAT3, a putative triacylgycerol synthase J. Lipid Res. 2006, 48, 583-591 10.1194/jlr.M600331-JLR200
25. Stone, S. J.; Levin, M. C.; Farese, R. V., Jr. Membrane topology and identification of key functional amino acid residues of murine acyl-CoA:diacylglycerol acyltransferase-2 J. Biol. Chem. 2006, 281 (52) 40273-40282 10.1074/jbc.M607986200
26. Hall, A. M.; Kou, K.; Chen, Z.; Pietka, T. A.; Kumar, M.; Korenblat, K. M.; Lee, K.; Ahn, K.; Fabbrini, E.; Klein, S.; Goodwin, B.; Finck, B. N. Evidence for regulated monoacylglycerol acyltransferase expression and activity in human liver J. Lipid Res. 2012, 53, 990-999 10.1194/jlr.P025536
27. Edwards, M. P.; Price, D. A. Role of Physicochemical Properties and Ligand Lipophilicity Efficiency in Addressing Drug Safety Risks Annu. Rep. Med. Chem. 2010, 45, 380-391 10.1016/S0065-7743(10)45023-X
28. Obach, R. S. The Prediction of Human Clearance from Hepatic Microsomal Metabolism Data Curr. Opin. Drug Discovery Dev. 2001, 4, 36-44
29. Passive permeability was assessed in Ralph Russ canine kidney cells: Di, L.; Whitney-Pickett, C.; Umland, J. O.; Zhang, H.; Zhang, X.; Gebhard, D. F.; Lai, Y.; Federico, J. J.; Davidson, R. E.; Smith, R.; Reyner, E. L.; Lee, C.; Feng, B.; Rotter, C.; Varma, M. V.; Kempshall, S.; Fenner, K.; El-Kattan, A. F.; Liston, T. E.; Troutman, M. D. Development of a New Permeability Assay Using Low-Efflux MDCKII Cells J. Pharm. Sci. 2011, 100, 4974-4985 10.1002/jps.22674
30. LogD values were determined using the shake-flask method with an octanol/water partition at pH 7.4. The assay method was adapted from published protocol using MS rather than HPLC for sample analysis: Hay, T.; Jones, R.; Beaumont, K.; Kemp, M. Modulation of the Partition Coefficient between Octanol and Buffer at Ph 7.4 and pKa to Achieve the Optimum Balance of Blood Clearance and Volume of Distribution for a Series of Tetrahydropyran Histamine Type 3 Receptor Antagonists Drug Metab. Dispos. 2009, 37, 1864-1870 10.1124/dmd.109.027888
31. Sun, H.; Bessire, A. J.; Vaz, A. Dirlotapide as a model substrate to refine structure-based drug design strategies on CYP3A4-catalyzed metabolism Bioorg. Med. Chem. Lett. 2012, 22, 371-6 10.1016/j.bmcl.2011.10.121
32. Sun, H.; Scott, D. O. Metabolism of 4-Aminopiperidine Drugs by Cytochrome P450s: Molecular and Quantum Mechanical Insights into Drug Design ACS Med. Chem. Lett. 2011, 2, 638-643 10.1021/ml200117z
33. For CYP2C9 crystal structure (PBD ID: 1R9O), see: Wester, M. R.; Yano, J. K.; Schoch, G. A.; Yang, C.; Griffin, K. J.; Stout, C. D.; Johnson, E. F. The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution J. Biol. Chem. 2004, 279, 35630-7 10.1074/jbc.M405427200
34. Pairwise analysis suggests this improvement is not driven only by decreased lipophilicity. See: Sun, H.; Keefer, C. E.; Scott, D. O. Systematic and pairwise analysis of the effects of aromatic halogenation and trifluoromethyl substitution on human liver microsomal clearance Drug Metab. Lett. 2011, 5, 232-242 10.2174/187231211798472575
35. Wang, X.; Zhang, L.; Krishnamurthy, D.; Senanayake, C. H.; Wipf, P. General solution to the synthesis of N-2-substituted 1,2,3-triazoles Org. Lett. 2010, 12, 4632-4635 10.1021/ol101965a
36. Dow, R. L.; Andrews, M. P.; Li, J.-C.; Gibbs, E. M.; Guzman-Perez, A.; LaPerle, J. L.; Li, Q.; Mather, D.; Munchhof, M. J.; Niosi, M.; Patel, L.; Perreault, C.; Tapley, S.; Zavadoski, W. Defining the key pharmacophore elements of PF-04620110: Discovery of a potent, orally-active, neutral DGAT-1 inhibitor Bioorg. Med. Chem. 2013, 21, 5081-5097 10.1016/j.bmc.2013.06.045
37. Ahn, K.; Boehm, M.; Cabral, S.; Carpino, P. A.; Futatsugi, K.; Hepworth, D.; Kung, D. W.; Orr, S.; Wang, J. Preparation of Pyrrolidinylimidazopyridinylpiperidinylmethanone Derivatives and Analogs for use as Diacylglycerol Acyltransferase 2 Inhibitors. WO13150416; 2013.
38. Qi, J.; Lang, W.; Geisler, J. G.; Wang, P.; Petrounia, I.; Mai, S.; Smith, C.; Askari, H.; Struble, G. T.; Williams, R.; Bhanot, S.; Monia, B. P.; Bayoumy, S.; Grant, E.; Caldwell, G. W.; Todd, M. J.; Liang, Y.; Gaul, M. D.; Demarest, K. T.; Connelly, M. A.The use of stable isotope-labeled glycerol and oleic acid to differentiate the hepatic functions of DGAT1 and -2 J. Lipid Res. 2012, 53, 1106-1116 10.1194/jlr.M020156
39. Smith, R.; Campbell, A.-M.; Coish, P.; Dai, M.; Jenkins, S.; Lowe, D.; O'Connor, S.; Su, N.; Wang, G.; Zhang, M.; Zhu, L. Preparation and use of arylalkyl acid derivatives for the treatment of obesity. US 20040224997, 2004.